Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen specific tumor cell killing by cytotoxic T cells

Abstract

Cytotoxic CD8+ T lymphocytes (CTLs) are key players of adaptive anti-tumor immunity based on their ability to specifically recognize and destroy tumor cells. Many cancer immunotherapies rely on unleashing CTL function. However, tumors can evade killing through strategies which are not yet fully elucidated. To provide deeper insight into tumor evasion mechanisms in an antigen-dependent manner, we established a human co-culture system composed of tumor and primary immune cells. Using this system, we systematically investigated intrinsic regulators of tumor resistance by conducting a complementary CRISPR screen approach. By harnessing CRISPR activation (CRISPRa) and CRISPR knockout (KO) technology in parallel, we investigated gene gain-of-function as well as loss-of-function across genes with annotated function in a colon carcinoma cell line. CRISPRa and CRISPR KO screens uncovered 187 and 704 hits respectively, with 60 gene hits overlapping between both. These data confirmed the role of interferon‑γ (IFN-γ), tumor necrosis factor α (TNF-α) and autophagy pathways and uncovered novel genes implicated in tumor resistance to killing. Notably, we discovered that ILKAP encoding the integrin-linked kinase-associated serine/threonine phosphatase 2C, a gene previously unknown to play a role in antigen specific CTL-mediated killing, mediate tumor resistance independently from regulating antigen presentation, IFN-γ or TNF-α responsiveness. Moreover, our work describes the contrasting role of soluble and membrane-bound ICAM-1 in regulating tumor cell killing. The deficiency of membrane-bound ICAM-1 (mICAM-1) or the overexpression of soluble ICAM-1 (sICAM-1) induced resistance to CTL killing, whereas PD-L1 overexpression had no impact. These results highlight the essential role of ICAM-1 at the immunological synapse between tumor and CTL and the antagonist function of sICAM-1.

Data availability

All data generated or analyzed are included in the manuscript. Source data files are provided for figure 2 and figure 3

Article and author information

Author details

  1. Ann-Kathrin Herzfeldt

    Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Ann-Kathrin Herzfeldt, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
  2. Marta Puig Gamez

    Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Marta Puig Gamez, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
  3. Eva Martin

    Department of Drug Discovery Sciences, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Eva Martin, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
  4. Lukasz Miloslaw Boryn

    Ardigen SA, Kraków, Poland
    Competing interests
    Lukasz Miloslaw Boryn, was an Ardigen S.A. employee. The funder provided support in the form of salaries for the authors..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8091-1071
  5. Praveen Baskaran

    Department of Global Computational Biology and Digital Sciences, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Praveen Baskaran, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2275-3516
  6. Heinrich J Huber

    Drug Discovery Sciences, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Heinrich J Huber, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4454-2971
  7. Michael Schuler

    Dept of Drug Discovery Services, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Michael Schuler, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
  8. John E Park

    Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim, Biberach an der Riss, Germany
    For correspondence
    john.park@boehringer-ingelheim.com
    Competing interests
    John E Park, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5674-6026
  9. Kim Lee Swee

    Department of Cancer Immunology and Immune Modulation, Boehringer Ingelheim, Biberach an der Riss, Germany
    Competing interests
    Kim Lee Swee, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..

Funding

Boehringer Ingelheim (none)

  • Ann-Kathrin Herzfeldt
  • Marta Puig Gamez
  • Eva Martin
  • Lukasz Miloslaw Boryn
  • Praveen Baskaran
  • Heinrich J Huber
  • Michael Schuler
  • John E Park
  • Kim Lee Swee

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Herzfeldt et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ann-Kathrin Herzfeldt
  2. Marta Puig Gamez
  3. Eva Martin
  4. Lukasz Miloslaw Boryn
  5. Praveen Baskaran
  6. Heinrich J Huber
  7. Michael Schuler
  8. John E Park
  9. Kim Lee Swee
(2023)
Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen specific tumor cell killing by cytotoxic T cells
eLife 12:e84314.
https://doi.org/10.7554/eLife.84314

Share this article

https://doi.org/10.7554/eLife.84314

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.